DEVA Stock Overview
Manufactures, markets, and sells pharmaceutical products in Turkey.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Deva Holding A.S. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₺69.30 |
| 52 Week High | ₺106.00 |
| 52 Week Low | ₺60.85 |
| Beta | -0.070 |
| 11 Month Change | 5.24% |
| 3 Month Change | -2.39% |
| 1 Year Change | -21.34% |
| 33 Year Change | 188.51% |
| 5 Year Change | 797.67% |
| Change since IPO | 36,782.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| DEVA | TR Pharmaceuticals | TR Market | |
|---|---|---|---|
| 7D | 3.7% | 1.0% | -1.3% |
| 1Y | -21.3% | 12.7% | 3.6% |
Return vs Industry: DEVA underperformed the TR Pharmaceuticals industry which returned 12.7% over the past year.
Return vs Market: DEVA underperformed the TR Market which returned 3.6% over the past year.
Price Volatility
| DEVA volatility | |
|---|---|
| DEVA Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in TR Market | 9.1% |
| 10% least volatile stocks in TR Market | 4.5% |
Stable Share Price: DEVA has not had significant price volatility in the past 3 months compared to the TR market.
Volatility Over Time: DEVA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 2,982 | Philipp Haas | www.deva.com.tr |
Deva Holding A.S. manufactures, markets, and sells pharmaceutical products in Turkey. The company provides antineoplastic and immunomodulating agents; dermatological products; sysyemic hormanal preparations; anti-infective and antiparasitic products for systemic use; food supplements; and electrolyte solutions. It also offers products in the areas of urogenital system and sex hormones, blood and blood forming organs, cardiovascular system, musculoskeletal system, nervous system, alimentary tract and metabolism, respiratory system, urinary systems, connective tissue, and sensory organs; and veterinary medicines.
Deva Holding A.S. Fundamentals Summary
| DEVA fundamental statistics | |
|---|---|
| Market cap | ₺13.53b |
| Earnings (TTM) | ₺2.89b |
| Revenue (TTM) | ₺10.96b |
4.8x
P/E Ratio1.3x
P/S RatioIs DEVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DEVA income statement (TTM) | |
|---|---|
| Revenue | ₺10.96b |
| Cost of Revenue | ₺6.62b |
| Gross Profit | ₺4.34b |
| Other Expenses | ₺1.45b |
| Earnings | ₺2.89b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 14.45 |
| Gross Margin | 39.63% |
| Net Profit Margin | 26.37% |
| Debt/Equity Ratio | 32.0% |
How did DEVA perform over the long term?
See historical performance and comparison